The Role of the Systemic Inflammatory Response as a Biomarker in Immunotherapy for Renal Cell Cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,Genetics,Molecular Medicine,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/BF03256333.pdf
Reference34 articles.
1. Dorr RT. Interferon-α in malignant and viral disease. Drugs 1993; 45(2): 177–211
2. Steineck G, Strander H, Carbin BE, et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma: a randomized trial. Acta Oncol 1990; 29(2): 155–62
3. Kreigmair M, Oberneder R, Hofstetter A. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 1995; 45(5): 758–62
4. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17(9): 2859–67
5. Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 1999; 353: 14–7
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Current state and challenges of emerging biomarkers for immunotherapy in hepatocellular carcinoma (Review);Experimental and Therapeutic Medicine;2023-11-03
2. Prognostic evaluation in patients with advanced cancer in the last months of life: ESMO Clinical Practice Guideline;ESMO Open;2023-04
3. Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers;Frontiers in Immunology;2023-02-15
4. The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment;Cancers;2019-12-04
5. C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma – A data from multi-institutional study in Japan;Urologic Oncology: Seminars and Original Investigations;2019-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3